5-Amino-1MQ Injection: What the Research Shows

5-Amino-1MQ injection is a research-only route of administration for a small-molecule NNMT inhibitor that has never been approved by the FDA for human use. In laboratory and animal studies, the compound is delivered subcutaneously so it bypasses digestion and reaches circulation quickly. No human clinical trial has established a safe or effective injected dose of 5-Amino-1MQ, so the numbers circulating online come from vendor guidance or user reports rather than clinical evidence.

What Is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic quinolinium compound studied as an inhibitor of nicotinamide N-methyltransferase, or NNMT. NNMT is an enzyme tied to nicotinamide metabolism and, in rodent models, to how fat cells store and burn energy.

In research settings it is handled as a lyophilized powder that must be reconstituted with bacteriostatic water before use. Key points researchers note:

• Class: a small molecule, not a peptide, even though it is often sold next to peptides.
• Research interest: NAD+ metabolism, adipocyte biology, and metabolic rate in mice.
• Human data: essentially none — no phase I trial, no published safety profile.
• Regulatory status: not approved as a drug, food, or dietary supplement in the United States.

Injection vs Oral Use: What's the Difference?

The debate over 5-amino-1mq oral vs injection comes down to absorption, convenience, and how much of the compound actually reaches circulation. Oral capsules are the form most vendors sell; reconstituted vials are the form people inject.

Factor	Oral (capsule or liquid)	Subcutaneous injection
Absorption	Passes through the gut; first-pass metabolism may lower bioavailability	Bypasses digestion and enters circulation more directly
Typical vendor format	50 mg or 100 mg capsules	5 mg or 10 mg lyophilized vials
Reported dose range	Often listed around 100–150 mg per day	Often listed around 1–10 mg per day
Sterility risk	Low if the product itself is clean	High if powder or water is contaminated
Human evidence	None	None

That gap is wide, and it is the main practical difference between the two routes: reported injected amounts are far smaller because none of the compound is lost to digestion.

Reported 5-Amino-1MQ Injection Dosage

Because there is no clinical dosing data, every figure below is anecdotal or vendor-suggested. Anyone searching for a 5-amino-1mq subcutaneous injection dosage should treat these numbers as unverified, not as medical guidance.

Reported protocol	Amount	Frequency	Evidence level
Low reported starting point	1–2.5 mg	Once daily	Anecdotal only
Common community range	2.5–5 mg	Once daily	Anecdotal only
High reported range	5–10 mg	Once daily	Anecdotal only
Rodent studies	Weight-based dosing	Daily injection	Animal data; not directly translatable

A full 10 mg injection dose would mean using an entire 10 mg vial in one syringe, which sits well above most reported starting points. People who reconstitute a 10 mg vial usually calculate concentration first — 1 mL of water yields 10 mg/mL — and then draw only a fraction of that volume.

Handling notes that show up in lab and user protocols:

1. Swab the vial stopper and the injection site with alcohol before every use.
2. Use a fresh syringe and needle for each draw.
3. Refrigerate reconstituted solution and discard it if it turns cloudy.
4. Never share vials, syringes, or needles with another person.

How It Compares With Other Research Compounds

Because they are marketed to the same metabolic-research audience, discussions of slu-pp-332 and 5-amino-1mq appear constantly in forums and vendor blogs. The two act through completely different mechanisms, so they are usually treated as separate experiments rather than substitutes.

Compound	Mechanism	Common form	Human data
5-Amino-1MQ	NNMT inhibitor	Oral capsule, injectable vial	None
SLU-PP-332	ERR agonist studied as an exercise mimetic	Injectable vial, oral	None
MOTS-c	Mitochondrial-derived peptide	Injectable vial	Early small human studies only

People following metabolic research often look into mots c and 5 amino 1mq in the same search session, but no published study has examined combining them. Unknown interactions are the strongest argument against stacking unapproved substances.

5-Amino-1MQ Side Effects and Safety Concerns

Any honest discussion of 5-amino-1mq side effects has to start with a disclaimer: the compound has no published human safety data. Everything below is either theoretical or self-reported, and none of it is confirmed in controlled studies.

• Injection site reactions: redness, pain, swelling, or lumps under the skin.
• Infection risk: non-sterile powder or water can introduce bacteria directly into tissue.
• Purity problems: research-grade vials are not held to pharmaceutical manufacturing standards.
• Unknown long-term effects: NNMT influences nicotinamide handling, and downstream effects on liver and nervous system metabolism have not been studied in people.
• Drug interactions: no interaction data exists with prescription medications.

Bloodwork monitoring is common among people who self-experiment with research chemicals, but monitoring does not substitute for clinical oversight. Anyone who is pregnant, breastfeeding, managing a medical condition, or taking prescription medication should speak with a healthcare professional before considering any unapproved compound. This article is informational only and is not medical advice.

Is 5-Amino-1MQ Injection Legal to Buy?

In the United States, 5-Amino-1MQ is not an approved drug and is generally sold with "for research use only" labeling. Marketing it as a supplement or drug for human consumption is not permitted.

That labeling matters because these products are not required to meet pharmaceutical standards. Independent testing of research vials has repeatedly found underdosed products and, in some cases, contaminants that should never be injected.

5-Amino-1MQ injection is not FDA-approved, has no established human dose, and carries unknown risks that no clinical trial has measured.

COMMON QUESTIONS

Frequently Asked Questions

Is 5-amino-1MQ injection safe for humans?

No human trials have tested 5-amino-1MQ, and the FDA has not approved it for any use. Reported risks include injection site reactions, infection from non-sterile products, and unknown long-term effects on nicotinamide metabolism. Anyone considering it should consult a healthcare professional first.

What is a typical 5-amino-1MQ injection dosage?

There is no established human dosage. Community and vendor reports commonly mention 1 mg to 5 mg injected subcutaneously once daily, with some users reporting up to 10 mg. These figures are anecdotal, and dosing from rodent studies does not translate directly to humans.

Can you inject 5-amino-1MQ from oral capsules?

No. Capsule powder is not manufactured to be sterile, so injecting it can cause serious infection or abscesses. Oral and injected forms also differ in strength, which is why the two routes are never interchangeable.